NervGen Pharma Corp.
NGEN.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.30M | -3.02M | -6.58M | -2.75M | -6.15M |
| Total Depreciation and Amortization | 10.00K | 10.10K | 10.10K | 9.70K | 11.30K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.84M | -636.80K | 3.35M | -376.30K | 2.99M |
| Change in Net Operating Assets | -138.20K | -217.00K | 573.50K | 247.70K | 531.00K |
| Cash from Operations | -4.59M | -3.86M | -2.65M | -2.87M | -2.61M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 18.10K | 18.30K | 18.20K | 17.60K | 18.00K |
| Cash from Investing | 18.10K | 18.30K | 18.20K | 17.60K | 18.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -25.20K | -25.20K | -25.20K | -25.20K | -25.20K |
| Issuance of Common Stock | 16.97M | 1.10M | 4.92M | 1.76M | 335.20K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -207.40K | -80.60K | -144.60K | -460.20K | 0.00 |
| Cash from Financing | 12.01M | 722.60K | 3.43M | 888.00K | 221.50K |
| Foreign Exchange rate Adjustments | 240.90K | -9.40K | 65.50K | 15.90K | -297.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7.68M | -3.13M | 869.70K | -1.95M | -2.67M |